Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Inoue (Osaka, Japan), M. Akira (Osaka, Japan), T. Kasai (Osaka, Japan), T. Arai (Osaka, Japan), K. Tachibana (Osaka, Japan), C. Sugimoto (Osaka, Japan), N. Takeuchi (Osaka, Japan), Y. Matsui (Osaka, Japan), Y. Kawabata (JP, Japan), T. Johkoh (JP, Japan), F. Sakai (JP, Japan), R. Egashira (JP, Japan), H. Sumikawa (JP, Japan), S. Shimizu (JP, Japan), T. Tanaka (JP, Japan), T. Takemura (JP, Japan), S. Izumi (JP, Japan), K. Sakamoto (JP, Japan), S. Matsumoto (JP, Japan), K. Hatanaka (JP, Japan), G. Matama (JP, Japan), T. Baba (JP, Japan), R. Mori (JP, Japan), H. Tomioka (JP, Japan), K. Tomii (JP, Japan), N. Hamada (JP, Japan), N. Nagata (JP, Japan), Y. Kondoh (JP, Japan), K. Kataoka (JP, Japan), T. Kishaba (JP, Japan), Y. Nakamura (JP, Japan), A. Yamagata (JP, Japan), A. Tanaka (JP, Japan), V. Poletti (Forli, Italy), M. Kitaichi (Wakayama, Japan). Idiopathic Pulmonary Fibrosis based on disease behavior: Workshop summary of a Japanese multicenter study. 1350

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe. Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016 Year: 2017 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Association of pulmonary and cardiac manifestations in patients with primary antiphospholipid syndrome: A review of the Serbian national cohort study Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice Year: 2015 Effect of Pulmonary Hypertension in exercise tolerance in patients with Chronic Obstructive Pulmonary Disease: A systematic review and meta-analysis Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Treatment dilemmas in sarcoidosis - a retrospective cohort study Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Value of community based Pulmonary Rehabilitation (PR) for patients with Interstitial Lung Disease (ILD): A retrospective review Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study Source: International Congress 2014 – Sarcoidosis Year: 2014 Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study. Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Health-related quality of life in idiopathic pulmonary fibrosis (IPF): First results based on the European IPF registry Source: International Congress 2014 – ILDs 1 Year: 2014